129 related articles for article (PubMed ID: 23178161)
1. Synthesis and biological evaluation of partially fluorinated antiprogestins and mesoprogestins.
Nickisch K; Elger W; Cessac J; Kesavaram N; Das B; Garfield R; Shi SQ; Amelkina O; Meister R
Steroids; 2013 Feb; 78(2):255-67. PubMed ID: 23178161
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of 11' imidazolyl antiprogestins and mesoprogestins.
Nickisch K; Elger W; Santhamma B; Garfield R; Killeen Z; Amelkina O; Schneider B; Meister R
Steroids; 2014 Dec; 92():45-55. PubMed ID: 25174783
[TBL] [Abstract][Full Text] [Related]
3. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone.
Attardi BJ; Burgenson J; Hild SA; Reel JR
J Steroid Biochem Mol Biol; 2004 Mar; 88(3):277-88. PubMed ID: 15120421
[TBL] [Abstract][Full Text] [Related]
4. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914.
Attardi BJ; Burgenson J; Hild SA; Reel JR; Blye RP
Mol Cell Endocrinol; 2002 Feb; 188(1-2):111-23. PubMed ID: 11911951
[TBL] [Abstract][Full Text] [Related]
5. Antiprogestins: mechanism of action and contraceptive potential.
Spitz IM; Croxatto HB; Robbins A
Annu Rev Pharmacol Toxicol; 1996; 36():47-81. PubMed ID: 8725382
[TBL] [Abstract][Full Text] [Related]
6. History and perspectives of antiprogestins from the chemist's point of view.
Teutsch G; Philibert D
Hum Reprod; 1994 Jun; 9 Suppl 1():12-31. PubMed ID: 7962457
[TBL] [Abstract][Full Text] [Related]
7. Next step in the development of mesoprogestins: the preclinical profile of EC313.
Błaszczak-Świątkiewicz K; Krupa A; Mnich E; Elger W; Oettel M; Nair H; Wierzbicki M; Sieroszewski P; Shaked Z
Front Endocrinol (Lausanne); 2023; 14():1201547. PubMed ID: 37766684
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of novel estrogen receptor-beta-sparing antiprogestins.
Sathya G; Jansen MS; Nagel SC; Cook CE; McDonnell DP
Endocrinology; 2002 Aug; 143(8):3071-82. PubMed ID: 12130573
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
Fuhrmann U; Hess-Stumpp H; Cleve A; Neef G; Schwede W; Hoffmann J; Fritzemeier KH; Chwalisz K
J Med Chem; 2000 Dec; 43(26):5010-6. PubMed ID: 11150172
[TBL] [Abstract][Full Text] [Related]
10. Syntheses and antigestagenic activity of mifepristone derivatives.
Hödl C; Raunegger K; Strommer R; Ecker GF; Kunert O; Sturm S; Seger C; Haslinger E; Steiner R; Strauss WS; Schramm HW
J Med Chem; 2009 Mar; 52(5):1268-74. PubMed ID: 19216549
[TBL] [Abstract][Full Text] [Related]
11. The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogestins.
Wagner BL; Pollio G; Giangrande P; Webster JC; Breslin M; Mais DE; Cook CE; Vedeckis WV; Cidlowski JA; McDonnell DP
Endocrinology; 1999 Mar; 140(3):1449-58. PubMed ID: 10067874
[TBL] [Abstract][Full Text] [Related]
12. Estrogen-induced stromal cell-derived factor-1 (SDF-1/Cxcl12) expression is repressed by progesterone and by Selective Estrogen Receptor Modulators via estrogen receptor alpha in rat uterine cells and tissues.
Glace L; Grygielko ET; Boyle R; Wang Q; Laping NJ; Sulpizio AC; Bray JD
Steroids; 2009; 74(13-14):1015-24. PubMed ID: 19665469
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antihormonal properties of novel 11β-benzoxazole-substituted steroids.
Jin C; Fix SE; Kepler JA; Cook CE
Bioorg Med Chem Lett; 2012 Feb; 22(4):1705-8. PubMed ID: 22260770
[TBL] [Abstract][Full Text] [Related]
14. 11 beta-substituted 13 beta-ethyl gonane derivatives exhibit reversal of antiprogestational activity.
Rao PN; Cessac JW; Blye RP; Kim HK
Steroids; 1998 Jan; 63(1):50-7. PubMed ID: 9437795
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and antiprogestational properties of novel 17-fluorinated steroids.
Nickisch K; Nair HB; Kesavaram N; Das B; Garfield R; Shi SQ; Bhaskaran SS; Grimm SL; Edwards DP
Steroids; 2013 Sep; 78(9):909-19. PubMed ID: 23607964
[TBL] [Abstract][Full Text] [Related]
16. Effects of D-ring substituents on antiprogestational (antagonist) and progestational (agonist) activity of 11 beta-aryl steroids.
Cook CE; Lee YW; Wani MC; Fail PA; Petrow V
Hum Reprod; 1994 Jun; 9 Suppl 1():32-9. PubMed ID: 7962467
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action and clinical effects of antiprogestins on the non-pregnant uterus.
Spitz IM; Robbins A
Hum Reprod Update; 1998; 4(5):584-93. PubMed ID: 10027612
[TBL] [Abstract][Full Text] [Related]
18. Effects of antiprogestins on the uterus.
Ouzounian S; Bouchard P; Chabbert-Buffet N
Womens Health (Lond); 2008 May; 4(3):269-80. PubMed ID: 19072476
[TBL] [Abstract][Full Text] [Related]
19. Progesterone receptor antagonists.
Spitz IM
Curr Opin Investig Drugs; 2006 Oct; 7(10):882-90. PubMed ID: 17086932
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoid receptor mediates the effect of progesterone on uterine natural killer cells.
Guo W; Li P; Zhao G; Fan H; Hu Y; Hou Y
Am J Reprod Immunol; 2012 Jun; 67(6):463-73. PubMed ID: 22380541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
